The full name

email@vos.com

Top Biotech News (01 Nov 2024)

Top Biotech News (01 Nov 2024)

RNA Editing Breakthrough by Wave Life Sciences

Summary: Wave Life Sciences Announces Success in First-Ever Human RNA Editing Clinical Trial, Marking a Critical Milestone in Precision Medicine”

Crescent Biopharma’s Double Win: Reverse Merger NASDAQ Debut and $200M Funding

Summary: GlycoMimetics, following unsuccessful Phase 2/3 clinical trials, accepted the transaction allocating 3.1% equity in the post-merger entity to its shareholders.

Lundbeck Takes Over Longboard Pharmaceuticals in $2.6 Billion Deal

Summary: The acquisition provided Lundbeck with rights to vexicaserin, an investigational therapy targeting 5-HT2C receptors involved in seizure severity modulation.

Roche Extends Gene Therapy Partnership with Dyno… Invests Over $1 Billion in AI-Driven Delivery Tool Design

Summary: After forming a gene therapy partnership with Dyno Therapeutics in 2020, they announced a $50 million upfront payment to design new adeno-associated virus (AAV) vectors as gene therapy delivery tools.

Novartis’ $2.9B MorphoSys bet stumbles as safety delays filing

Summary: Novartis Faces Setback in Acquisition Strategy. Months post-acquisition, the company disclosed safety concerns that may result in multi-year delays for the core asset’s approval submission.

Subscribe
to the latest updates in the newsletter

Related Solutions

Organoid Service

  • Disease Modeling
  • Oncology
  • Organoid
Organoid Service

Research service

  • Cosmetics
  • OECD TG
  • Zebrafish
Research service

Technical service

  • Bioinfomatics
  • Holotomography
  • Molecular biology
  • Spatial Biology
Technical service

Next Articles

Connect with Us

By submitting your details, you confirm that you have reviewed and agree with the Lambda Biologics Privacy Policy.